All In Biotech

Drug Trial Radar · NCT06760819

A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)

A Phase 2 Open-label Basket Study to Evaluate the Efficacy and Safety of Orally Administered Reversible Tyrosine Kinase Inhibitor BAY 2927088 in Participants With Metastatic or Unresectable Solid Tumors With HER2-activating Mutations

Last checked: Nov 19, 2026Latest source record: Nov 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

111

Planned (sponsor's estimate)

Start

Feb 13, 2025

Primary completion

Feb 2, 2029

Study completion Oct 26, 2029

Sponsor

Lead sponsor
BayerBayer (BAYRY)
Sponsor type
Industry
First posted
Jan 7, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Researchers are looking for a better way to treat people who have solid tumors with HER2-activating mutations. Before a treatment can be approved for people to take, researchers do clinical trials to better understand its safety and how it works. In this trial, the researchers want to learn how well BAY2927088 (sevabertinib) works in people with different types of solid tumors with HER2 mutations. These include tumors in the colon or rectum, the uterus and the cervix (lower part of the uterus), the breast, the bladder, and the biliary tract (includes gall bladder and bile ducts) as well as other types of solid tumors with the exception of people with advanced non-small cell lung cancer (NSCLC). Solid tumors may have specific changes or mutations to a gene called human epidermal growth receptor-2 (HER2). This leads to the formation of an abnormal form of HER2 protein in the cancer cells, resulting in increased cell growth. The study treatment, BAY2927088, is expected to block the abnormal HER2 protein which may stop the spread of cancer. The trial will include about 111 participants who are at least 18 years old. All the participants will take 20 mg of BAY2927088 as tablets by mouth. The participants will take treatments in 3-week periods called cycles. These 3-week cycles will be repeated throughout the trial. The participants can take BAY2927088 until their cancer gets worse, until they have medical problems, or until they leave the trial. During the trial, the doctors will take imaging scans of different parts of the body to study the spread of cancer and will check heart health using echocardiogram or cardiac magnetic resonance imaging (MRI) and electrocardiogram (ECG). The doctors will also take blood and urine samples and do physical examinations to check the participants' health. They will ask questions about how the participants are feeling and if they have any medical problems.

Conditions

  • Advanced Solid Tumors
  • HER2 Mutation

Interventions

  • BAY2927088Drug

    tablet, oral

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Objective Response Rate (ORR) per RECIST 1.1 as assessed by BICRTime frame: From start of study intervention until the first documented progression, or death from any cause, or end of study (up to approximately 3 years), whichever comes first

Locations

54 sites in 11 countries. Site status is shown where the registry gives one.

  • UAB O'Neal Comprehensive Cancer Center - The Kirklin Clinic of UAB Hospital

    Birmingham, Alabama · Not yet recruiting

  • City of Hope - Duarte Cancer Center

    Duarte, California · Recruiting

  • Florida Cancer Specialists & Research Institute - Fort Myers Cancer Center - Gladiolus

    Fort Myers, Florida · Recruiting

  • Dana-Farber Cancer Institute - Oncology Department

    Boston, Massachusetts · Recruiting

  • Brigette Harris Cancer Pavilion at Henry Ford Cancer Center - Detroit

    Detroit, Michigan · Withdrawn

  • Profound Research -OMG - TriAtria Cancer Center

    Farmington Hills, Michigan · Withdrawn

  • Cleveland Clinic - Oncology Department

    Cleveland, Ohio · Recruiting

  • SCRI Oncology Partners

    Nashville, Tennessee · Recruiting

  • The University of Texas MD Anderson Cancer Center - Texas Medical Center

    Houston, Texas · Recruiting

  • Gynecology Oncology clinic at UW Medical Center - Montlake

    Seattle, Washington · Withdrawn

  • UW Health Carbone Cancer Center

    Madison, Wisconsin · Not yet recruiting

  • NSW Health - Blacktown Hospital

    Blacktown, New South Wales, Australia · Recruiting

  • Macquarie University Hospital - Oncology Department

    Sydney, New South Wales, Australia · Recruiting

  • ICON Cancer Centre - Southport

    Southport, Queensland, Australia · Not yet recruiting

  • Queen Elizabeth II Health Sciences Centre | Oncology

    Halifax, Nova Scotia, Canada · Withdrawn

  • Princess Margaret Cancer Centre | Medical Oncology and Hematology

    Toronto, Ontario, Canada · Recruiting

  • Research Institute of the McGill University Health Centre | Women Health's Research Unit

    Montreal, Quebec, Canada · Withdrawn

  • Peking University First Hospital - Oncology Department

    Beijing, Beijing Municipality, China · Recruiting

  • Beijing Cancer Hospital - Oncology Department

    Beijing, Beijing Municipality, China · Recruiting

  • Hunan Cancer Hospital - Oncology Department

    Changsha, Hunan, China · Not yet recruiting

  • Fudan University Shanghai Cancer Center - Oncology Department

    Shanghai, Shanghai Municipality, China · Recruiting

  • Zhongshan Hospital, Fudan University

    Shanghai, Shanghai Municipality, China · Recruiting

  • Sir Run Run Shaw Hospital, Zhejiang Univ. School of Medicine - Oncology Department

    Hangzhou, Zhejiang, China · Not yet recruiting

  • Rigshospitalet Copenhagen University Hospital | Oncology Department

    Copenhagen, Capital Region / Region Hovedstaden, Denmark · Recruiting

  • Aarhus University Hospital | Oncology Department - Clinical Research Unit

    Aarhus N, Central Denmark Region / Region Midtjylland, Denmark · Withdrawn

  • Odense University Hospital | Svendborg Sygehus - Oncology Department

    Odense, Region of Southern Denmark / Region Syddanmark, Denmark · Recruiting

  • Centre Hospitalier Lyon Sud - Service oncologie medicale

    Pierre-Bénite, Auvergne-Rhône-Alpes, France · Recruiting

  • CHU Brest - Hopital La Cavale Blanche - service oncologie medicale

    Brest, Brittany Region, France · Recruiting

  • Centre Oscar Lambret - Service Oncologie

    Lille, Hauts-de-France, France · Not yet recruiting

  • Institut Gustave Roussy - Departement d'Innovation Therapeutique et d'Essais Precoces (DITEP)

    Villejuif, Île-de-France Region, France · Recruiting

  • Institut Bergonie - Unicancer Nouvelle Aquitaine - Service Oncologie medicale

    Bordeaux, New Aquitaine, France · Recruiting

  • ICM - Institut du Cancer de Montpellier - Val d'Aurelle - CIPP

    Montpellier, Occitanie, France · Not yet recruiting

  • Azienda USL IRCCS di Reggio Emilia_Arcispedale Santa Maria Nuova - S.C. Oncologia Provinciale

    Reggio Emilia, Emilia-Romagna, Italy · Not yet recruiting

  • Fondazione Policlinico Universitario Agostino Gemelli IRCCS - UOC Oncologia Medica

    Rome, Lazio, Italy · Recruiting

  • Fondazione IRCCS Istituto Nazionale dei Tumori - S. C. Oncologia Medica 1

    Milan, Lombardy, Italy · Recruiting

  • Istituto Europeo di Oncologia s.r.l - Ginecologia Oncologica Medica

    Milan, Lombardy, Italy · Not yet recruiting

  • Aichi Cancer Center Hospital

    Nagoya, Aichi-ken, Japan · Recruiting

  • National Cancer Center Hospital East (NCCHE) - Kashiwa Campus

    Kashiwa, Chiba, Japan · Recruiting

  • Hokkaido University Hospital

    Sapporo, Hokkaido, Japan · Recruiting

  • Kindai University Hospital

    Sakai, Osaka, Japan · Recruiting

Showing 40 of 54 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.